CXCL5 and neoplasm: In 2016, Wang et al. used a murine prostate adenocarcinoma model to demonstrate that YAP-driven CXCL5 production by cancer cells can lead MDSCs to the tumour site through heterotypic CXCL5 binding to CXCR2 receptors [36].